Pharma Mar, S.A. (BME: PHM)

Market Cap	739.79M
Revenue (ttm)	158.80M
Net Income (ttm)	-1.76M
Shares Out	17.54M
EPS (ttm)	-0.10
PE Ratio	n/a
Forward PE	29.91
Dividend	0.65 (1.54%)
Ex-Dividend Date	Jun 12, 2024

Volume	36,003
Open	41.38
Previous Close	41.46
Day's Range	41.38 - 42.56
52-Week Range	26.16 - 43.92
Beta	0.20
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About Pharma Mar

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung ca...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1986
• Employees: 509
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: PHM

Financial Performance

In 2023, Pharma Mar's revenue was 158.15 million, a decrease of -19.45% compared to the previous year's 196.34 million. Earnings were 1.14 million, a decrease of -97.70%.